Asset Details
Do you wish to reserve the book?
Is There Any Difference in Preferences Between Patients and Physicians? Evidence From Anti‐Hyperglycemic Medications Choices for Type 2 Diabetes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Is There Any Difference in Preferences Between Patients and Physicians? Evidence From Anti‐Hyperglycemic Medications Choices for Type 2 Diabetes
Do you wish to request the book?
Is There Any Difference in Preferences Between Patients and Physicians? Evidence From Anti‐Hyperglycemic Medications Choices for Type 2 Diabetes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Is There Any Difference in Preferences Between Patients and Physicians? Evidence From Anti‐Hyperglycemic Medications Choices for Type 2 Diabetes
2026
Overview
Aims This study aimed to explore differences in preferences between Chinese patients with type 2 diabetes mellitus (T2D) and physicians when selecting anti‐hyperglycemic medications. Materials and Methods We conducted a discrete choice experiment (DCE) involving 1784 patients (face‐to‐face surveys) and 168 physicians (online questionnaires) across eastern, central, and western China. Seven treatment attributes were assessed: HbA1c reduction, hypoglycemia risk, cardiovascular benefits, gastrointestinal adverse events, weight change, mode of administration, and monthly out‐of‐pocket cost. Preference heterogeneity was explored using latent class model. Results Patients placed the greatest importance on monthly out‐of‐pocket cost, treatment efficacy, and hypoglycemia risk, whereas physicians prioritized hypoglycemia risk, cardiovascular benefits, and treatment efficacy. Notably, physicians tended to overestimate patients' willingness to pay for treatment benefits. Specifically, patients were willing to pay 277 CNY (39 USD) for cardiovascular benefits, whereas physicians estimated that patients would be willing to pay 864 CNY (121 USD). Latent class analysis identified substantial heterogeneity in both groups. In particular, the largest patient subgroup was strongly cost‐sensitive, with preferences driven primarily by financial burden, whereas no directly corresponding physician subgroup was observed. Conclusion Patients and physicians differ in how they prioritize diabetes medication attributes, especially regarding efficacy, cardiovascular benefit, and cost. Shared decision‐making should account for these differences to support value‐concordant, patient‐centered diabetes care. Highlights This study reveals substantial differences in anti‐hyperglycemic medication preferences between Chinese patients with T2D and physicians. Patients prioritized out‐of‐pocket cost and treatment efficacy, while physicians emphasized hypoglycemia risk and cardiovascular benefits. These discrepancies highlight the need for enhanced shared decision‐making to align treatment choices with patient values and improve adherence. Differences in patient and physician preferences for anti‐hyperglycemic medication attributes in China.
Publisher
Wiley Publishing Asia Pty Ltd,John Wiley & Sons, Inc,Wiley
Subject
/ Aged
/ anti‐hyperglycemic medications
/ China
/ Diabetes
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - psychology
/ Disease
/ Female
/ Glycated Hemoglobin - analysis
/ Humans
/ Hypoglycemic Agents - therapeutic use
/ Insulin
/ Male
/ Original
